Long-Acting Injectable Antipsychotics in Adolescents with Bipolar Disorder
Publication: Journal of Child and Adolescent Psychopharmacology
Volume 35, Issue Number 2
Abstract
Background: Bipolar disorder often begins in adolescence or early adulthood, characterized by recurrent manic episodes that can lead to neurodegenerative brain changes and functional decline. While several oral second-generation antipsychotics are Food and Drug Administration (FDA)-approved for mania, adherence to maintenance treatment is frequently poor due to factors such as anosognosia, cognitive dysfunction, impulsivity, side effects aversion, and substance use. Long-acting injectable (LAI) antipsychotics, approved for adults with bipolar mania or schizoaffective disorder (bipolar type), offer a potential solution for adolescents with similar conditions. This study reports on the efficacy of LAI antipsychotics in managing bipolar mania in adolescents, tracking outcomes over up to a year with baseline and follow-up Young Mania Rating Scale (YMRS) assessments.
Methods: The study included 116 adolescents with a mean age of 16.17 years (66% male, 48% white, 23% black). Of these, 73% were diagnosed with bipolar mania and 22% with schizoaffective disorder, bipolar type. The mean illness duration was 1.9 years, with a baseline YMRS score of 33.8 and a body mass index (BMI) of 23.4 kg/m². LAI antipsychotics administered included aripiprazole, paliperidone, and risperidone, given at intervals of 1, 2, or 3 months.
Results: YMRS scores showed substantial improvement, declining to 21.7 at 1 month, 12.3 at 2 months, 4.9 at 6 months, and 3.0 at 1 year. Common side effects were increased appetite and weight gain (mean BMI rose to 26.3 kg/m²). There were no dropouts, although 12% of participants switched formulations due to side effects. Notably, 86.2% of adolescents improved sufficiently to return to school or work. While 28.4% experienced depressive episodes, there were no suicide attempts or deaths during the 4- to 14-month follow-up.
Discussion: This study demonstrates that LAI antipsychotics can effectively stabilize adolescents with bipolar mania or schizoaffective disorder, bipolar type, showing a marked decline in YMRS scores and high rates of remission and functional recovery. Despite the lack of FDA approval for LAI antipsychotics in those younger than 18, our results from off-label use suggest significant efficacy and tolerability. Further FDA clinical trials are needed to explore LAI antipsychotic formulations in adolescents to address the needs of this high-risk, nonadherent population.
Get full access to this article
View all available purchase options and get full access to this article.
References
Aggarwal A, Schrimpf L, Lauriello J. Aripiprazole long-acting injectable for maintenance treatment of bipolar I disorder in adults. Clin Schizophr Relat Psychoses 2018;11(4):221–223;
Biuckians A, Miklowitz DJ, Kim EY. Behavioral activation, inhibition and mood symptoms in early-onset bipolar disorder. J Affect Disord 2007;97(1–3):71–76;
Cerullo MA, Strakowski SM. The prevalence and significance of substance use disorders in bipolar type I and II disorder. Subst Abuse Treat Prev Policy 2007;2:29;
Ching CRK, Hibar DP, Gurholt TP, et al.;. ENIGMA Bipolar Disorder Working Group. What we learn about bipolar disorder from large-scale neuroimaging: Findings and future directions from the ENIGMA bipolar disorder working group. Hum Brain Mapp 2022;43(1):56–82;
Coletti DJ, Leigh E, Gallelli KA, et al. Patterns of adherence to treatment in adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2005;15(6):913–917;
Deas D. Adolescent substance abuse and psychiatric comorbidities. J Clin Psychiatry 2006;67(Suppl 7):18–23.
Escamilla MA, Zavala JM. Genetics of bipolar disorder. Dialogues Clin Neurosci 2008;10(2):141–152;
Freund N, Juckel G. Bipolar disorder: Its etiology and how to model in rodents. Methods Mol Biol 2019;2011:61–77;
Goldstein BI, Liu SM, Zivkovic N, et al. The burden of obesity among adults with bipolar disorder in the United States. Bipolar Disord 2011;13(4):387–395;
Grover S, Avasthi A, Chakravarty R, et al. Factors associated with lifetime suicide attempts: Findings from the bipolar disorder course and outcome study from India (BiD-CoIN study). Nord J Psychiatry 2023;77(3):227–233;
Grover S, Chakrabarti S, Sahoo S. Prevalence and clinical correlates of residual symptoms in remitted patients with bipolar disorder: An exploratory study. Indian J Psychiatry 2020;62(3):295–305;
Grunze H, Schaefer M, Scherk H, et al. Comorbid Bipolar and alcohol use disorder-A therapeutic challenge. Front Psychiatry 2021;12:660432;
Hossain S, Mainali P, Bhimanadham NN, et al. Medical and psychiatric comorbidities in Bipolar disorder: Insights from national inpatient population-based study. Cureus 2019;11(9):e5636;
Huang Y, Zhang Z, Lin S, et al. Cognitive impairment mechanism in patients with Bipolar disorder. Neuropsychiatr Dis Treat 2023;19:361–366;
Jain A, Mitra P. Bipolar Disorder. In: StatPearls. StatPearls: Treasure Island (FL); 2023.
Mendez I, Castro-Fornieles J, Lera-Miguel S, et al. Functional impairment and clinical correlates in adolescents with bipolar disorder compared to healthy controls. A case-control study. J Can Acad Child Adolesc Psychiatry 2020;29(3):149–164.
Patel NC, DelBello MP, Keck PE Jr, et al. Ethnic differences in maintenance antipsychotic prescription among adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2005;15(6):938–946;
Patel RS, Virani S, Saeed H, et al. Gender differences and comorbidities in U.S. Adults with bipolar disorder. Brain Sci 2018;8(9):168;
Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: Primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006;163(2):217–224;
Priya L, Moorthy B. A case of hypersexuality in a patient receiving aripiprazole for schizophrenia. Case Rep Psychiatry 2021;2021:5557211;
Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264(19):2511–2518.
Saxena K, Kurian S, Saxena J, et al. Mixed states in early-onset bipolar disorder. Psychiatr Clin North Am 2020;43(1):95–111;
Singh J, Chen G, Canuso CM. Antipsychotics in the treatment of bipolar disorder. Handb Exp Pharmacol 2012(212):187–212;
Sonne SC, Brady KT. Bipolar disorder and alcoholism. Alcohol Research & Health 2024;26;103.
Spoorthy MS, Chakrabarti S, Grover S. Comorbidity of bipolar and anxiety disorders: An overview of trends in research. World J Psychiatry 2019;9(1):7–29;
Taddeo D, Egedy M, Frappier JY. Adherence to treatment in adolescents. Paediatr Child Health 2008;13(1):19–24;
Tondo L, Visioli C, Preti A, et al. Bipolar disorders following initial depression: Modeling predictive clinical factors. J Affect Disord 2014;167:44–49;
Tuplin EW, Holahan MR. Aripiprazole, A drug that displays partial agonism and functional selectivity. Curr Neuropharmacol 2017;15(8):1192–1207;
Verdoux H, Bourgeois M. Conséquences à court terme de l’interruption d’un traitement par sels de lithium [Short-term sequelae of lithium discontinuation]. Encephale 1993;19(6):645–650.
Vieta E, Berk M, Schulze TG, et al. Bipolar disorders. Nat Rev Dis Primers 2018;4:18008;
Youn H, Lee MS, Jeong HG, et al. Evaluation of factors associated with medication adherence in patients with bipolar disorder using a medication event monitoring system: A 6-month follow-up prospective study. Ann Gen Psychiatry 2022;21(1):33;
Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry 1978;133:429–435;
